DHEA prevents mineralo- and glucocorticoid receptor-induced chronotropic and hypertrophic actions in isolated rat cardiomyocytes

Endocrinology

Volumn 154, Issue 3, 2013, Pages 1271-1281

  Mannic, Tiphaine ^a   Mouffok, Mounira ^a   Python, Magaly ^a   Yoshida, Takehisa ^a,c   Maturana, Andres D ^c   Vuilleumier, Nicolas ^b   Rossier, Michel F ^a,b,d  

^a Endocrinology Diabetes and Metabolic Diseases   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c NAGAOKA UNIVERSITY OF TECHNOLOGY   (Japan)

^d Service of Clinical Chemistry and Toxicology   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL T TYPE; DACTINOMYCIN; GLUCOCORTICOID RECEPTOR; MINERALOCORTICOID RECEPTOR; PRASTERONE;

ANIMAL CELL; ARTICLE; CHRONOTROPISM; CONTROLLED STUDY; HEART MUSCLE CELL; HEART PROTECTION; HYPERTROPHY; NEWBORN; NONHUMAN; PATCH CLAMP; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ALDOSTERONE; ANIMALS; ANTIOXIDANTS; CALCIUM CHANNELS, T-TYPE; CARDIOTONIC AGENTS; CELL ENLARGEMENT; CELLS, CULTURED; DEHYDROEPIANDROSTERONE; GENE EXPRESSION; HEART RATE; MYOCYTES, CARDIAC; RATS; RECEPTORS, GLUCOCORTICOID; RECEPTORS, MINERALOCORTICOID;

EID: 84874613296     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1784     Document Type: Article

References (25)

1. Pitt B, Zannad F, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. New Engl J Med. 1999;341:709-717.
2. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
3. Gaeggeler HP, Gonzalez-Rodriguez E, Jaeger NF, et al. Mineralocorticoid versus glucocorticoid receptor occupancy mediating aldosterone-stimulated sodium transport in a novel renal cell line. J Am Soc Nephrol. 2005;16:878-891.
4. Rossier MF, Lenglet S, Vetterli L, Python M, Maturana A. Corticosteroids and redox potential modulate spontaneous contractions in isolated rat ventricular cardiomyocytes. Hypertension. 2008;52: 721-728.
5. Lalevee N, Rebsamen MC, Barrere-Lemaire S, et al. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res. 2005; 67:216-224.
6. Maturana A, Lenglet S, Python M, Kuroda S, Rossier MF. Role of the T-type calcium channel CaV3.2 in the chronotropic action of corticosteroids in isolated rat ventricular myocytes. Endocrinology. 2009;150:3726-3734.
7. Rossier MF, Python M, Maturana AD. Contribution of mineralocorticoid and glucocorticoid receptors to the chronotropic and hypertrophic actions of aldosterone in neonatal rat ventricular myocytes. Endocrinology. 2010;151:2777-2787.
8. Dooley R, Harvey BJ, Thomas W. The regulation of cell growth and survival by aldosterone. Front Biosci. 2011;16:440-457.
9. Nakamura S, Yoshimura M, Nakayama M, et al. Possible association of heart failure status with synthetic balance between aldosterone and dehydroepiandrosterone in human heart. Circulation. 2004;110:1787-1793.
10. Celec P, Starka L. Dehydroepiandrosterone-is the fountain of youth drying out? Physiol Res. 2003;52:397-407.
11. Dumas dlR, Savineau JP, Bonnet S. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther. 2010;126:186-199.
12. Gupte SA, Tateyama M, Okada T, Oka M, Ochi R. Epiandrosterone, a metabolite of testosterone precursor, blocks L-type calcium channels of ventricular myocytes and inhibits myocardial contractility. J Mol Cell Cardiol. 2002;34:679-688.
13. Tamagno E, Aragno M, Boccuzzi G, et al. Oxygen free radical scavenger properties of dehydroepiandrosterone. Cell Biochem Funct. 1998;16:57-63.
14. Chemin J, Monteil A, Briquaire C, et al. Overexpression of T-type calcium channels in HEK-293 cells increases intracellular calcium without affecting cellular proliferation. FEBS Lett. 2000;478:166-172.
15. Ram R, Van Wagoner DR. Aldosterone antagonism as an antiarrhythmic approach for atrial arrhythmias in heart failure. J Cardiovasc Electrophysiol. 2006;17:542-543.
16. Barrett-Connor E, Khaw KT, Yen SS. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 1986;315:1519-1524.
17. Mitchell LE, Sprecher DL, Borecki IB, et al. Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation. 1994; 89:89-93.
18. Huang B, Qin D, Deng L, Boutjdir M, Sherif N. Reexpression of T-type Ca2+channel gene and current in post-infarction remodeled rat left ventricle. Cardiovasc Res. 2000;46:442-449.
19. Perez-Reyes E. Three for T: Molecular analysis of the low voltageactivated calcium channel family. Cell Mol Life Sci. 1999;56:660-669.
20. Bhuiyan MS, Fukunaga K. Targeting α-1 receptor signaling by endogenous ligands for cardioprotection. Expert Opin Ther Targets. 2011;15:145-155.
21. Monassier L, Bousquet P. α Receptors: From discovery to highlights of their implications in the cardiovascular system. Fundam Clin Pharmacol. 2002;16:1-8.
22. Ela C, Barg J, Vogel Z, Hasin Y, Eilam Y. α Receptor ligands modulate contractility, Ca++influx and beating rate in cultured cardiac myocytes. J Pharmacol Exp Ther. 1994;269:1300-1309.
23. Novakova M, Bruderova V, Sulova Z, et al. Modulation of expression of the β receptors in the heart of rat and mouse in normal and pathological conditions. Gen Physiol Biophys. 2007;26:110-117.
24. Camporez JP, Akamine EH, Davel AP, Franci CR, Rossoni LV, Carvalho CR. Dehydroepiandrosterone protects against oxidative stress-induced endothelial dysfunction in ovariectomized rats. J Physiol. 2011;589:2585-2596.
25. Chevalier M, Gilbert G, Lory P, Marthan R, Quignard JF, Savineau JP. Dehydroepiandrosterone (DHEA) inhibits voltage-gated T-type calcium channels. Biochem Pharmacol. 2012;83:1530-1539.